Influence of abiraterone acetate on neuroendocrine differentiation in chemotherapy ‐naive metastatic castration‐resistant prostate cancer
ConclusionsWe hypothesized that AA might not significantly lead to progression of NED of mCRPC in general. Furthermore, we found there was heterogeneity in changes of NED markers in different mCRPC patients during AA treatment. Serial CgA and NSE evaluation might help clinicians guide clinical treatment of mCRPC patients.
Source: The Prostate - Category: Urology & Nephrology Authors: Baijun Dong, Liancheng Fan, Yanqing Wang, Chenfei Chi, Xiaowei Ma, Rui Wang, Wen Cai, Xiaoguang Shao, Jiahua Pan, Yinjie Zhu, Xun Shangguan, Zhixiang Xin, Jianian Hu, Shaowei Xie, Xiaonan Kang, Lixin Zhou, Wei Xue Tags: ORIGINAL ARTICLE Source Type: research
More News: Abiraterone Acetate | Brain | Cancer | Cancer & Oncology | Chemotherapy | Neurology | Prostate Cancer | Urology & Nephrology